Uptake Difference by Somatostatin Receptors in a Patient with

Neuroendocrine Tumor: 99mTc-Octreotide Uptake in the Lung without

Uptake in Liver Lesions by Assadi, Majid et al.
Molecular Imaging and Radionuclide Therapy, published by Galenos Publishing. 
128
Ad dress for Cor res pon den ce: Majid Assadi MD, Bushehr University of Medical Sciences, The Persian Gulf Nuclear Medicine Research Center, Bushehr, Iran 
Phone: 0098-771-2580169 E-mail: assadipoya@yahoo.com Received: 21.07.2013 Ac cep ted: 23.11.2013 
Elahe Pirayesh1, Mahasti Amoui1, Majid Assadi2
1Shahid Beheshti University of Medical Sciences, Shohada-e Tajrish Medical Center, Department of Nuclear Medicine, Tehran, Iran
2Bushehr University of Medical Sciences, The Persian Gulf Nuclear Medicine Research Center, Bushehr, Iran
Abstract
The diagnostic value of somatostatin receptor scintigraphy (SRS) in detecting tumors has been assessed in a number of studies. 
We present a 30-year-old female with a history of eight months cough and left shoulder pain. Radiologic evaluation showed 
pulmonary mass and hepatic lesions, which were pathologically diagnosed as neuroendocrine carcinoma. 99mTc-octreotide 
scan demonstrated that the pulmonary lesion was positive for somatostatin receptor (SSTR), while the liver metastases were 
SSTR negative. The present case highlights the significance of a differential uptake pattern by somatostatin receptors in SRS 
in patients with neuroendocrine tumors.
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Öz
Somatostatin reseptör sintigrafisinin (SRS) tümör saptamadaki tanısal değeri bir dizi çalışmada değerlendirilmiştir. Bu yazıda 
sekiz aylık öksürük ve sol omuz ağrısı öyküsü olan 30 yaşındaki bir kadın hasta sunulmaktadır. Radyolojik değerlendirme ile 
akciğerde kitle ve karaciğer lezyonları saptanan hastada patolojik olarak nöroendokrin karsinom saptandı. 99mTc-oktreotid 
taramasında akciğer lezyonu somatostatin reseptörü (SSTR) için pozitif iken karaciğer metastazları SSTR negatif idi. Bu olgu 
nöroendokrin tümörlerde SRS ile somatostatin reseptörlerinin farklı tutulum göstermesinin önemini vurgulamaktadır.
Anahtar kelimeler: Radyonüklid görüntüleme, nöroendokrin tümör, 99mTc-oktreotid, reseptör, somatostatin
Nöroendokrin Tümörlü Bir Hastada Somatostatin Reseptörleri ile Tutulum Farklılığı: 
Akciğerde 99mTc-Oktreotid Tutulumu Mevcutken Karaciğer Lezyonlarında Tutulum 
Saptanmadı
Uptake Difference by Somatostatin Receptors in a Patient with 
Neuroendocrine Tumor: 99mTc-Octreotide Uptake in the Lung without 
Uptake in Liver Lesions
 Case Report
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Introduction 
Somatostatin receptor scintigraphy (SRS) is a functional 
imaging modality that is used to evaluate neuroendocrine 
tumors (1). The diagnostic value of SRS in detecting tumors 
has been assessed in a number of studies (1). Its uptake 
has been shown in different cell lines such as lymphocytes, 
fibroblasts, and endothelium (2). Herein, we present a 
30-year-old female with neuroendocrine tumor of the lung 
and liver, with pulmonary 99mTc-octreotide uptake on SRS.
Case Report
A 30-year-old female, who had been suffering from a 
non-productive cough for 8 months and left shoulder pain, 
was found to have a large mass in the left lung (Figure 
1). Further evaluation by abdominal sonography and 
computed tomography (CT) scan revealed multiple hepatic 
lesions (Figure 2). A CT guided biopsy of the liver lesions 
was performed. The liver sections showed poorly cohesive 
nests of epithelial cells with plasmocytoid and signet ring 
morphology, and solitary infiltrating cells with vascular 
permeation in a non-cirrhotic liver parenchyma, suggesting 
metastatic undifferentiated carcinoma with signet ring 
feature.
The immunohistochemistry (IHC) results were positive 
for EMA, CK, Chromogranin, Ki67 (1%) indices, but were 
negative for TTF1, GCDFP15, Heppar, Ck7, and Ck20 
indices. IHC findings were in favor of metastatic low-grade 
neuroendocrine carcinoma.
She was healthy with an unremarkable past medical 
history, and she was not on any medications. Scintigraphic 
imaging was done 15 minutes and 3 hours after IV injection 
of 740 MBq (20 m mCi) 99mTc-Edda-tricine-Hynic-Tyro-
octreotide, and an increased radiotracer uptake in the lung 
mass was identified (Figure 3). On planar images, there 
was a suspicious photopenic area in the posterior view of 
the liver (Figure 4). A SPECT was done and revealed some 
photopenic regions in the liver, compatible with the hepatic 
masses on CT images (Figure 5).
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Figure 1. Computed tomography scan showing a large mass in the left 
lung field
Figure 2. Computed tomography scan showing multiple hypodense regions 
in the right liver lobe
Figure 3. Technetium-99m-labeled octreotide acetate scintigraphy in the 
planar view of the thorax (anterior). This was performed 15 minutes after 
injection of 740 MBq technetium-99m-labeled octreotide acetate. There was 
an area of abnormal uptake in the left lung field
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Literature Review and Discussion
Molecular imaging alters the diagnosis and 
treatment of patients with neuroendocrine tumors. 
SSTR scintigraphy has become the method of choice 
for functional imaging of these tumors (3). SRS with 
[111In-DTPA0] octreotide has established its role in 
the diagnosis and staging of gastroenteropancreatic 
neuroendocrine tumors (GEP-NETs) (4). In addition, 
radiolabelled metaiodobenzylguanidine (MIBG) has 
been applied for many years to detect carcinoid tumors 
(5). Somatostatin analogues have been labelled with 
different positron-emitting isotopes, such as Gallium-68 
(68Ga) and Copper-64 (64Cu) (6). Furthermore, other 
PET radiotracers such as 18F-dihydroxy-phenyl-alanine 
(18F-DOPA) and 11C-labelled 5-hydroxytryptophan (11C-5-
HTP) were introduced with promising results in detecting 
GEP-NETs (7). 
Somatostatin receptors are overexpressed at the cell 
membrane and peritumoral vessels of a large variety of 
NETs. Although, various SSTR subtypes are expressed in 
tumors, SSTR2 is the predominant one, and it provides 
the molecular basis for clinical application of SS analogues 
for diagnostic and therapeutic purposes (8). However, 
it is well known that tumors frequently acquire cellular 
heterogeneity (9). This is related to tumorigenesis that is 
not a static entity: the tumor initiates from a genetically 
normal cell and proliferates into billions of malignant 
cells, during which it accumulates many mutations (9). 
There is strong evidence for the co-existence of genetically 
divergent tumor cell clones within a variety of tumors, and 
it has gained attention especially regarding response to 
therapy (9). It could also be a potential factor for sampling 
error (10). An IHC investigation reported heterogeneity in 
SSTR subtype expression between primary vs. metastatic 
NETs, as well as among hepatic metastases (11). There is 
also evidence for heterogeneity of Ki67 index in metastatic 
NETs (11).
In endocrine tumors, the presence of SSTRs are 
associated with well differentiation, low grade tumor 
and good response to somatostatin analog (octreotide) 
treatment (12,13).
While most well-differentiated endocrine tumors and 
islet cell carcinomas are SSTR-positive, and therefore 
responsive to somatostatin analog therapy; the poorly 
differentiated endocrine tumors are generally SSTR-
negative and hardly benefit from somatostatin analog 
therapy (12,13,14,15).
The present case shows an uptake difference by 
somatostatin receptors in somatostatin receptor scintigraphy 
of a NET in the lung and its liver metastases, which can be 
explained by tumor heterogeneity and a different pattern 
of SSTR expression. In addition, it highlights the importance 
of SPECT study in detecting photopenic regions. Nuclear 
physicians should also be aware that all metastases do not 
necessarily appear as hot lesions. Photopenic areas require 
special emphasis. 
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Figure 4. Technetium-99m-labeled octreotide acetate scintigraphy in the 
planar view of the abdomen (anterior and posterior). This was performed 
3 hours after injection of 740 MBq technetium-99m-labeled octreotide 
acetate. There was a suspicious photopenic area in the posterior view of 
the right lobe of liver
Figure 5. Technetium-99m-labeled octreotide acetate scintigraphy in the 
SPECT mode. It revealed some photopenic regions in the liver, compatible 
with the hepatic masses on computed tomography images
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